Table of Content

1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Overview
1.1 Product Overview and Scope of DPP-4 Inhibitors for Type 2 Diabetes Treatment
1.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Type
1.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Type (2024-2034)
1.2.2 Sitagliptin
1.2.3 Linagliptin
1.2.4 Vildagliptin
1.2.5 Saxagliptin
1.2.6 Alogliptin
1.2.7 Others
1.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Application
1.3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Value by Application: (2024-2034)
1.3.2 Offline Retail Pharmacy
1.3.3 Hospitals and Clinics
1.3.4 E-commerce and Internet Medical Care
1.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Estimates and Forecasts
1.4.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue 2024-2034
1.4.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales 2024-2034
1.4.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Competition by Manufacturers
2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Manufacturers (2024-2024)
2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Manufacturers (2024-2024)
2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Average Price by Manufacturers (2024-2024)
2.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of DPP-4 Inhibitors for Type 2 Diabetes Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of DPP-4 Inhibitors for Type 2 Diabetes Treatment, Product Type & Application
2.7 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Competitive Situation and Trends
2.7.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest DPP-4 Inhibitors for Type 2 Diabetes Treatment Players Market Share by Revenue
2.7.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Retrospective Market Scenario by Region
3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2024-2034
3.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2024-2024
3.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2024-2034
3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2024-2034
3.3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2024-2024
3.3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2024-2034
3.4 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
3.4.1 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034)
3.4.3 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
3.5.1 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034)
3.5.3 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
3.6.1 Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034)
3.6.3 Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
3.7.1 Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034)
3.7.3 Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034)
3.8.3 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2024-2034)
4.1.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2024-2024)
4.1.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2024-2034)
4.1.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2024-2034)
4.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2024-2034)
4.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2024-2024)
4.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2024-2034)
4.2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2024-2034)
4.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price by Type (2024-2034)
5 Segment by Application
5.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2024-2034)
5.1.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2024-2024)
5.1.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2024-2034)
5.1.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2024-2034)
5.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2024-2034)
5.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2024-2024)
5.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2024-2034)
5.2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2024-2034)
5.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price by Application (2024-2034)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.1.4 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.2.4 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Eli Lilly and Company
6.3.1 Eli Lilly and Company Corporation Information
6.3.2 Eli Lilly and Company Description and Business Overview
6.3.3 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.3.4 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.3.5 Eli Lilly and Company Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Boehringer Ingelheim
6.5.1 Boehringer Ingelheim Corporation Information
6.5.2 Boehringer Ingelheim Description and Business Overview
6.5.3 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.5.5 Boehringer Ingelheim Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Takeda Pharmaceutical
6.6.1 Takeda Pharmaceutical Corporation Information
6.6.2 Takeda Pharmaceutical Description and Business Overview
6.6.3 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.7.5 Takeda Pharmaceutical Recent Developments/Updates
6.8 Mitsubishi Tanabe Pharma
6.8.1 Mitsubishi Tanabe Pharma Corporation Information
6.8.2 Mitsubishi Tanabe Pharma Description and Business Overview
6.8.3 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.8.4 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.8.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
6.9 LG Life Sciences
6.9.1 LG Life Sciences Corporation Information
6.9.2 LG Life Sciences Description and Business Overview
6.9.3 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.9.4 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.9.5 LG Life Sciences Recent Developments/Updates
6.10 Sanwa Kagaku Kenkyusho
6.10.1 Sanwa Kagaku Kenkyusho Corporation Information
6.10.2 Sanwa Kagaku Kenkyusho Description and Business Overview
6.10.3 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.10.5 Sanwa Kagaku Kenkyusho Recent Developments/Updates
6.11 Dong-A Pharmaceuticals
6.11.1 Dong-A Pharmaceuticals Corporation Information
6.11.2 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Description and Business Overview
6.11.3 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.11.4 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.11.5 Dong-A Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Chain Analysis
7.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process
7.4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Marketing
7.4.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Channels
7.4.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Distributors
7.5 DPP-4 Inhibitors for Type 2 Diabetes Treatment Customers
8 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Dynamics
8.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Trends
8.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Drivers
8.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Challenges
8.4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Competitive Situation by Manufacturers in 2022
Table 4. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) of Key Manufacturers (2024-2024)
Table 5. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Manufacturers (2024-2024)
Table 6. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market DPP-4 Inhibitors for Type 2 Diabetes Treatment Average Price (US$/K Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of DPP-4 Inhibitors for Type 2 Diabetes Treatment, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of DPP-4 Inhibitors for Type 2 Diabetes Treatment, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of DPP-4 Inhibitors for Type 2 Diabetes Treatment, Product Type & Application
Table 12. Global Key Manufacturers of DPP-4 Inhibitors for Type 2 Diabetes Treatment, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in DPP-4 Inhibitors for Type 2 Diabetes Treatment as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2024-2024) & (M Units)
Table 18. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2024-2024)
Table 19. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2024-2034) & (M Units)
Table 20. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2024-2034)
Table 21. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2024-2024)
Table 23. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2024-2034)
Table 25. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2024) & (M Units)
Table 27. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034) & (M Units)
Table 28. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2024) & (M Units)
Table 32. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034) & (M Units)
Table 33. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2024-2024) & (M Units)
Table 37. Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2024-2034) & (M Units)
Table 38. Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2024) & (M Units)
Table 42. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034) & (M Units)
Table 43. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2024) & (M Units)
Table 47. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034) & (M Units)
Table 48. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) by Type (2024-2024)
Table 51. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) by Type (2024-2034)
Table 52. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2024-2024)
Table 53. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2024-2034)
Table 54. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Type (2024-2024)
Table 55. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Type (2024-2034)
Table 56. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2024-2024)
Table 57. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2024-2034)
Table 58. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Type (2024-2024)
Table 59. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Type (2024-2034)
Table 60. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) by Application (2024-2024)
Table 61. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) by Application (2024-2034)
Table 62. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2024-2024)
Table 63. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2024-2034)
Table 64. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Application (2024-2024)
Table 65. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Application (2024-2034)
Table 66. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2024-2024)
Table 67. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2024-2034)
Table 68. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Application (2024-2024)
Table 69. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Application (2024-2034)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 73. Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Product
Table 74. Merck Recent Developments/Updates
Table 75. AstraZeneca Corporation Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 78. AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Product
Table 79. AstraZeneca Recent Developments/Updates
Table 80. Eli Lilly and Company Corporation Information
Table 81. Eli Lilly and Company Description and Business Overview
Table 82. Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 83. Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Product
Table 84. Eli Lilly and Company Recent Developments/Updates
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 88. Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Product
Table 89. Novartis Recent Developments/Updates
Table 90. Boehringer Ingelheim Corporation Information
Table 91. Boehringer Ingelheim Description and Business Overview
Table 92. Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 93. Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Product
Table 94. Boehringer Ingelheim Recent Developments/Updates
Table 95. Bristol-Myers Squibb Corporation Information
Table 96. Bristol-Myers Squibb Description and Business Overview
Table 97. Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 98. Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Product
Table 99. Bristol-Myers Squibb Recent Developments/Updates
Table 100. Takeda Pharmaceutical Corporation Information
Table 101. Takeda Pharmaceutical Description and Business Overview
Table 102. Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 103. Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Product
Table 104. Takeda Pharmaceutical Recent Developments/Updates
Table 105. Mitsubishi Tanabe Pharma Corporation Information
Table 106. Mitsubishi Tanabe Pharma Description and Business Overview
Table 107. Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 108. Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Product
Table 109. Mitsubishi Tanabe Pharma Recent Developments/Updates
Table 110. LG Life Sciences Corporation Information
Table 111. LG Life Sciences Description and Business Overview
Table 112. LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 113. LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Product
Table 114. LG Life Sciences Recent Developments/Updates
Table 115. Sanwa Kagaku Kenkyusho Corporation Information
Table 116. Sanwa Kagaku Kenkyusho Description and Business Overview
Table 117. Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 118. Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Product
Table 119. Sanwa Kagaku Kenkyusho Recent Developments/Updates
Table 120. Dong-A Pharmaceuticals Corporation Information
Table 121. Dong-A Pharmaceuticals Description and Business Overview
Table 122. Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 123. Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Product
Table 124. Dong-A Pharmaceuticals Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. DPP-4 Inhibitors for Type 2 Diabetes Treatment Distributors List
Table 128. DPP-4 Inhibitors for Type 2 Diabetes Treatment Customers List
Table 129. DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Trends
Table 130. DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Drivers
Table 131. DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Challenges
Table 132. DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of DPP-4 Inhibitors for Type 2 Diabetes Treatment
Figure 2. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Type in 2022 & 2034
Figure 4. Sitagliptin Product Picture
Figure 5. Linagliptin Product Picture
Figure 6. Vildagliptin Product Picture
Figure 7. Saxagliptin Product Picture
Figure 8. Alogliptin Product Picture
Figure 9. Others Product Picture
Figure 10. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 11. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Application in 2022 & 2034
Figure 12. Offline Retail Pharmacy
Figure 13. Hospitals and Clinics
Figure 14. E-commerce and Internet Medical Care
Figure 15. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 16. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size (2024-2034) & (US$ Million)
Figure 17. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (2024-2034) & (M Units)
Figure 18. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Average Price (US$/K Unit) & (2024-2034)
Figure 19. DPP-4 Inhibitors for Type 2 Diabetes Treatment Report Years Considered
Figure 20. DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Share by Manufacturers in 2022
Figure 21. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Manufacturers in 2022
Figure 22. The Global 5 and 10 Largest DPP-4 Inhibitors for Type 2 Diabetes Treatment Players: Market Share by Revenue in 2022
Figure 23. DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 24. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 25. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2024-2034)
Figure 26. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2024-2034)
Figure 27. United States DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 28. Canada DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 29. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2024-2034)
Figure 30. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2024-2034)
Figure 31. Germany DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 32. France DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 33. U.K. DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 34. Italy DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 35. Russia DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 36. Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2024-2034)
Figure 37. Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2024-2034)
Figure 38. China DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. Japan DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. South Korea DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 41. India DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 42. Australia DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 43. China Taiwan DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 44. Southeast Asia DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 45. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2024-2034)
Figure 46. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2024-2034)
Figure 47. Mexico DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 48. Brazil DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 49. Argentina DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 50. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2024-2034)
Figure 51. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2024-2034)
Figure 52. Turkey DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 53. Saudi Arabia DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 54. UAE DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 55. Global Sales Market Share of DPP-4 Inhibitors for Type 2 Diabetes Treatment by Type (2024-2034)
Figure 56. Global Revenue Market Share of DPP-4 Inhibitors for Type 2 Diabetes Treatment by Type (2024-2034)
Figure 57. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Type (2024-2034)
Figure 58. Global Sales Market Share of DPP-4 Inhibitors for Type 2 Diabetes Treatment by Application (2024-2034)
Figure 59. Global Revenue Market Share of DPP-4 Inhibitors for Type 2 Diabetes Treatment by Application (2024-2034)
Figure 60. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Application (2024-2034)
Figure 61. DPP-4 Inhibitors for Type 2 Diabetes Treatment Value Chain
Figure 62. DPP-4 Inhibitors for Type 2 Diabetes Treatment Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed